News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ViroStatics Demonstrates Clinical Proof of Concept for Dual Antiviral Anti-Hyperactivation AV-HALT Drugs


3/2/2011 8:55:15 AM

BOSTON--(BUSINESS WIRE)--An analysis of immune markers measured in a sub-study of ViroStatics’ proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load. VS411 is a first-generation AV-HALT (antiviral-hyperactivation limiting therapeutic) designed to reduce both viral load and the state of chronic activation that exists in HIV-infected individuals. The analysis was presented today at the 18th Conference on Retroviruses and Opportunistic Infections.

Read at BioSpace.com

comments powered by Disqus
   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES